On October 27th, Runben Biotechnology Co., Ltd (Runben Bio.) released its financial report for the third quarter of 2023, which is also the first financial report published by the company since its listing.
According to the financial report, Runben Bio. achieved operating revenue of 824 million yuan ($112.6 million) in the first three quarters, a year-on-year growth of 20.90%. The net profit attributable to shareholders of the listed company was 181 million yuan ($24.73 million), a year-on-year increase of 37.47%.
Looking at the quarterly performance, in the third quarter, Runben Bio. achieved operating revenue of 244 million yuan, a year-on-year increase of 0.91%. The net profit attributable to shareholders of the listed company was 61.2653 million yuan ($8.37 million), a year-on-year increase of 15.75%.
It is worth noting that Runben Bio. achieved revenue of 856 million yuan ($116.97 million) in 2022. Based on the performance revealed in this report, not only did the company almost catch up with last year’s annual revenue in the third quarter alone but it also has the potential to surpass the 1 billion yuan mark this year.
Furthermore, Runben Bio. previously expressed on the interactive platform its intention to actively expand overseas markets, promote the unique value and image of Chinese brands, and focus on developing and cultivating stable and high-quality overseas customer resources. The company aims to make Runben brand a globally recognized international brand by a wide range of consumers.
